First-line chemoimmunotherapy versus chemotherapy in PD-L1-negative patients with non-small-cell lung cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Immunotherapy"
DOI: 10.2217/imt-2021-0208
Abstract: Background: In PD-L1-negative patients with advanced non-small-cell lung cancer (NSCLC), conclusive evidence in support of specific treatments remains lacking. Objectives: The efficacy of first-line chemoimmunotherapy versus chemotherapy alone was compared. Methods: Eligible randomized studies that included… read more here.
Keywords: chemoimmunotherapy versus; versus chemotherapy; first line; chemoimmunotherapy ... See more keywords